News & Trends - Biotechnology
Australian biopharma announces new acquisition

Biotech News: Melbourne-based Telix Pharmaceuticals is advancing its position in the field of radiopharmaceuticals by entering into an agreement to acquire QSAM Biosciences, a U.S.-based company specialising in the development of therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
The centerpiece of this strategic acquisition is QSAM’s lead investigational drug, Samarium-153-DOTMP (153Sm-DOTMP), a bone-seeking targeted radiopharmaceutical candidate. Utilising a “next generation” chelating agent, the proprietary formulation of Samarium-153 radioisotope in 153Sm-DOTMP shows promise in two major applications – pain management of bone metastases and osteosarcoma therapy, including in paediatric patients.
Telix, known for its focus on urologic oncology, neuro-oncology, and musculoskeletal oncology, sees this alignment with 153Sm-DOTMP as a natural progression in their therapeutic focus areas. The drug has exhibited evidence of safety, efficacy, and future commercial utility in pre-clinical and early clinical trials, presenting potential improvements in the treatment and management of late-stage metastatic disease.
Dr Christian Behrenbruch, Managing Director and Group CEO of Telix, emphasised the transformative potential of the acquisition, stating, “The acquisition of QSAM provides Telix with an additional near-term therapeutic pipeline asset, further differentiating our innovation position in radiopharmaceuticals and building depth in Telix’s key disease focus areas of urological and musculoskeletal oncology.”
153Sm-DOTMP stands out with a significantly improved safety profile, reduced off-target irradiation through more targeted delivery, and a streamlined production system, offering a cost-effective and quality of life-enhancing alternative to standard-of-care treatments. Telix envisions its potential commercialisation as a milestone that builds on an established reimbursement pathway for this class of drugs.
Recent pre-clinical and clinical data support the use of 153Sm-DOTMP in the pain management of prostate cancer bone metastases, addressing a critical unmet patient need after progression from other radionuclide and radiation therapies. Telix is optimistic about the broader application of the drug in metastatic lung and breast cancer, where patients often face brain and bone metastases, underscoring the potential for enhanced quality-of-life palliative care.
Further adding to the significance of this acquisition, 153Sm-DOTMP has received Orphan Drug and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. This expands Telix’s portfolio to include a potential treatment for a disease predominantly affecting children and young adults, aligning with Telix’s established focus in musculoskeletal oncology.
Dr Behrenbruch added “Samarium is a highly optimal radionuclide for treating bone metastases, and the combination of ODD and PRDD status with Telix’s demonstrated experience in pharmacy-based cold-kit distribution has strong potential for a rapid pathway to commercialisation of this asset.”
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics

Government’s claim of progress in genomics falls flat while it fails to uphold the fundamental rights of Aussies
The government has unveiled Cancer Australia’s National Framework for Genomics in Cancer Control, a strategic plan designed to guide healthcare […]
MoreNews & Trends - Pharmaceuticals

Healthcare sector’s political donations: What to expect ahead of the federal election
Ahead of the upcoming federal election, attention turns to the financial contributions to major political parties. The Australian Electoral Commission’s […]
MoreNews & Trends - Pharmaceuticals

‘Underinvestment in gynae cancer has left critical gaps,’ says ANZGOG Chair
Ovarian cancer is the deadliest women’s cancer, with the latest statistics revealing a five-year survival rate of just 49%. Alarmingly, […]
MoreNews & Trends - MedTech & Diagnostics

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo
The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]
More